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pn the last three decades, the U.S. life expectancy has been
rolonged by about one or two years each decade due to
dvances in cardiovascular medicine. This improvement is
he result of the development of better therapies rather than
ardiovascular disease (CVD) prevention. Despite this im-
rovement, CVD continues to be the leading cause of death
y far (Table 1), and its prevalence is increasing (1).
The picture is particularly grim when looking at the
lobal burden of CVD. In comparing mortality data for
990 versus estimates for 2020, developing countries will
xperience about a 100% increase in mortality due to CVD.
or developed countries, such as the U.S., cardiovascular
ortality is expected to increase by about 20%, from
pproximately five million deaths annually in 1990 to six
illion in 2020 (2). In terms of the combined incidence of
oronary artery disease (CAD) and CAD mortality, in
eveloped countries, for the same time period we expect to
ee a 29% increase among women and a 48% increase
mong men. In developing countries, it is astonishing: we
xpect to see a 120% increase in CAD and CAD mortality
mong women and 137% in men (3) (Table 2). So, while we
re certainly prolonging life, a huge problem remains.
N OPPORTUNITY FOR CLINICIANS
s this an opportunity for clinicians? Absolutely. There will
e an increasing number of patients to treat, due at least in
art to an increase in the elderly population. According to
n American College of Cardiology workforce analysis, the
ercentage of patients more than 65 years of age treated per
ardiologist will increase from 8.6% today to 24.9% in 2020
Fig. 1) (4). Obviously, we have had modest success in
rolonging life, and CVD appears later today, but the great
roblem facing all of us relates to disease prevention. In the
.S. today, 34.4% of the population have one major risk
actor for CVD, and 27.9% have two or more major risk
actors (5). The World Health Organization has analyzed
eaths in 2000 attributable to leading risk factors, and the
rst three are blood pressure, tobacco, and cholesterol.
ther risk factors that are growing rapidly include lack of
ruit and vegetable intake, high body mass index, and
hysical inactivity. If you think about that, this is largely a
escription of the metabolic syndrome. If you examine the
From the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-c
osée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical
enter, New York, New York.ata, the most important reason why we are dealing with an
ncreased prevalence of CVD and increased mortality ap-
ears to be that we are failing at disease prevention.
There are economic issues as well that are contributing to
he problems we face today. Like many world economies,
ncluding Europe, health care spending in the U.S. is closely
elated to the country’s gross domestic product (GDP). The
nnual percent change in private health expenditures follows
he GDP at about a four-year delay. That is, as U.S. GDP
ncreases or decreases, four years later you will see a very
imilar increase or decrease in private health expenditures.
All of these factors—an increase in the number of
ndividuals over 65 years of age, little CVD prevention, and
country’s economic status—all contribute to a high de-
and for cardiologists. Now the question becomes: how are
e going to increase the supply of cardiologists?
The 35th Bethesda Conference recommended two ap-
roaches to confront a growing shortage of cardiovascular
pecialists (Table 3) (6). First and foremost, we have to
ncrease the number of cardiologists; second, we need to
mprove practitioner efficiency, productivity, and satisfac-
ion.
One approach recommended by the Conference is to
horten the cardiology training program (7). Instead of three
ears of medicine for a general clinical cardiologist, there
ould be two years of general medical training followed by
hree years of cardiology, one year of which will be very
uch focused on prevention. In terms of general medicine,
here are fewer and fewer people who want to go into
nternal medicine today because the program is just too
ong. There is a strong need to recruit people, and one of the
ays to encourage more people to enter is to make the
raining program shorter.
There is a second issue that is tied to policies of this
ountry: the number of foreign-born individuals permitted
o enter the U.S. and remain here to work is decreasing
harply. At the present time, about one-third of all cardi-
logy trainees in this country are international medical
raduates (IMG) (8). As we decrease the number of IMGs,
ow can we increase the number of cardiologists coming out
t the end of the clinical training track?
Predicting out to 2050, there will come a time when we
annot go any further with improving CVD except through
isease prevention, although this is very expensive. We also
redict that well into the future there will be too many
ardiologists. But at this moment, we need many more
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The Future of Academic Cardiovascular Medicine October 4, 2005:1A–4Aardiologists because the mortality and prevalence of CVD
re continuing to increase sharply and will continue to do so
or the next 10 to 15 years.
ESEARCH FUNDING:
HALLENGES AND OPPORTUNITIES
hat is happening with research funding in this country?
here once we only saw opportunities, today we face major
hallenges: the number of applications submitted to the
ational Institutes of Health (NIH) between 1993 and
003, in terms of new grants and grant renewals, has been
at even though the budget at NIH has doubled during this
ame 10-year period (9). At least two-thirds of the increase
n the NIH budget has been necessary for the grants that are
pproved because much more expensive research is being
onducted today. Unfortunately, the number of grants being
warded from NIH to investigators 35 years old and
ounger is decreasing, falling from 23% of all NIH awards
n 1980 to just 4% in 2000 (10,11).
For senior investigators, the new and renewal application
rocess is just part of your life. However, younger cardiol-
gists often ask whether it is really necessary to do all of this.
f you have such thoughts, it means you probably do not
ave the heart for investigation. If you make your choices
ased on issues relating to whether or not the situation offers
ore or less security, you are not an investigator.
In reviewing biomedical research in the U.S., it has been
able 1. Leading Causes of Death in the U.S. by Gender: 2002
Males Females
otal CVD (preliminary) 403,555 456,064
ancer 288,768 268,503
ccidents 69,257 37,485
hronic lower respiratory diseases 60,713 64,103
iabetes mellitus 34,301 38,948
lzheimer’s disease 16,989 41,877
ource: Centers for Disease Control and Prevention. Excerpted from Table D. Natl
ital Stat Rep. 2005;53(17):1–89. Title of table as published: Deaths and Percentage
f Total Deaths for the 10 Leading Causes of Death, by Sex: United States, 2005.
able 2. Estimate of Ischemic Heart Disease Mortality (Thousan
990 and 2020
Region
Women
1990 2020
ME 838 1,107
SE 559 702
otal developed countries 1,397 1,809
ndia 556 1,197
hina 377 684
AI 227 552
SA 117 263
atin America 169 412
iddle East 291 717
otal developing countries 1,737 3,825
orld 3,134 5,634ith permission from Yusuf S, et al. Circulation 2001;104:2746–53.
EME  established market economies; FSE  formerly socialistic economies; OAI nbelievably important economically as well as in every
ther respect, and it has had a large impact on this country.
his is good news. Unfortunately, at the present time, the
ews regarding NIH funding is not so good. We have gone
rom a doubling of the NIH budget in 1999 to 2004 to a
rojected increase for 2005 of just 2.6%. Compounding the
nancial problems is the significant shift of monies from
cience into biodefense; while that is still funding science, it
s certainly not funding the biomedical science we are used
o working with as investigators. This shift in priorities is a
eality and will continue for the foreseeable future. It has
een projected that, to just keep up with what we were
oing in terms of biomedical research, we need an 8% to 9%
nnual budget increase from now on, so this 2.6% increase
n 2005 is a problem.
Another important issue goes back to our IMGs. A very
nteresting paper was recently published arguing that as U.S.
ominance in science decreases, reaching equivalency with
urope, there will be a greater need for IMGs (12). This has
lot to do with progress in science depending heavily on the
orldwide exchange of ideas, information, data, materials,
nd people. There has been a great concern, expressed in
ditorials published in various journals, that in many re-
pects the U.S. has become isolated, and the common belief
s that there is no need to pay attention to what is happening
igure 1. Estimated population 65 years old and older with cardiovascular
isease per cardiologist (1980 to 2050). Source: American College of
ardiology Workforce Analysis, Internal Task Force on Workforce Re-
ort, 2003. With permission from Fye WB. J Am Coll Cardiol 2004;33:
21–32.
y Region and Gender and Projected Changes Between
Men
Increase 1990 2020 % Increase
32 829 1,209 46
26 468 712 52
29 1,297 1,921 48
115 619 1,405 127
81 386 811 110
143 233 581 149
125 92 222 141
144 179 444 148
146 319 874 174
120 1,828 4,337 137
80 3,125 6,258 100ds) b
%other Asian and Pacific Island countries; SSA  sub-Saharan Africa.
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October 4, 2005:1A–4A The Future of Academic Cardiovascular Medicineutside our borders. However, this is occurring at the same
ime that our dominance in science is being challenged by
he growth of scientific research done elsewhere. One
olution is to bring more IMGs into the U.S., not as
linicians but as investigators. Unfortunately, the hurdles for
oreign students have gotten much greater in the last few
ears.
Another issue worth mentioning has to do with politics.
he current political scenario has been heavily criticized in
erms of science, in particular the 1,000 committees who
ctually advise the federal government. A recent commen-
ary in The New England Journal of Medicine noted that
oliticians are free to do whatever they want, but there are
oncerns relating to the injection of politics into science and
o what extent science is a priority in the current adminis-
ration (13).
The last of the major issues confronting biomedical
esearch is the financial status of academic medical centers.
nvestigators in academic centers are being asked to do too
any tasks, leaving too little time for creativity. This has
ad an incredibly negative impact on young investigators
rying to find mentors.
An emphasis on research offers major economic dividends
o society. According to six research papers authored by nine
istinguished economists working independently of each
ther, advances in medical research generate dramatic re-
urns in health and in economics. Specifically, a summary
eport by the Albert and Mary Lasker Foundation docu-
ents that the “extended healthy lives” of Americans is in
reat part due to advances in medical research. While these
dvances consume $45 billion annually, the return on this
nvestment is staggering. The work of the nine economists,
ublished first in the report Exceptional Returns (14,15),
stimated that increases in life expectancy in the U.S.
etween 1970 and 1990 were worth roughly $2.8 trillion a
ear. This represents a rate of return on research investment
100 to 1. Reduced mortality from CVD alone was
stimated to be worth $1.5 trillion a year.
The problem politicians have with this kind of investing
s that it takes a long time to come to fruition—they will not
ee any thing from today’s investments until 10 years from
ow. The short-sighted nature of this approach led the late
able 3. Shortage of Cardiologists: ACC Recommendations
rom the 35th Bethesda Conference
Increase the number of cardiologists
Increase training capacity—“short track”
Improve recruitment to cardiovascular medicine—international
medical graduates
Encourage experienced cardiologists to delay retirement
Improve practitioner efficiency, productivity, and satisfaction
Promote the cardiovascular care team approach
Improve cardiovascular practice organizations
Use technology to enhance patient care and facilitate continuing
medical education
Enhance the job-matching process
ource: 35th Bethesda Conference, J Am Coll Cardiol 2004;44.ary Lasker, for whom the foundation is named, to once ybserve: “If you think research is expensive, try disease” (14).
am mentioning this because I hope academic institutions
nd scientists will have a significant impact in dealing with
ur political leaders and encouraging long-term science
unding in this country.
Although there are problems with present funding at the
IH and many general hurdles for investigators, other
rganizations are doing very well in stepping up to offer
olutions, such as the American College of Cardiology and
he American Heart Association. Of course, there is an
ncredible amount of money invested by industry too, and
his has to be taken into account in any discussion of
edical research. The tremendous investment by philan-
hropists in the U.S. also is unique; it does not happen in
any other parts of the world, but here it supports science
ith about $20 billion a year of funding. Consequently,
espite the hurdles, the good news for young investigators is
his: if you like research, you will make it. The door of entry
ay be different than it was for previous generations, but
hat door is there.
ERSONAL SEARCH AND APPROACH
o find the door and establish a career in research, you must
e practical. First, consider who you are and what you are
ood at. Know yourself, do not fool yourself; never get into
omething you do not have the talent for. Second, once you
iscover what you are good at, there are three critical issues:
entorship, pursuing your work in depth, and then staying
ocused. This applies to anything you do in life, at least
nything that you do well. You must invest in your talent,
ut do not invest in what you do not have talent for because
hat is very costly. So how well do you know yourself? That
s an issue that has no simple answer, but is something
here you may be helped by people who know you and are
lose to you, including mentors.
Think about the characteristics of creativity or innova-
ion. The current thesis of creativity and innovation says
hat first you have to be free, but freedom involves risk. If
ou do not like to take risks, forget it; you are not an
nvestigator. The second set of characteristics of creativity is
ltruism, communication, and team effort. This is new,
ecause the theory used to hold that you were the only one
aking it and nobody else. Right now, if you want to make
t alone, forget it. Today, creativity and innovation requires
team effort and altruism; you give and you get. That is
hat a team means. A team is not just your friends. This is
hy the word altruism applies and why it is very important
or success.
The third characteristic of creativity is confidence and
assion, while the final characteristics are that of being
onsistent and hard-working. Some of these things are
enetic, and some are acquired; to me, being consistent and
ard-working is genetic. There are people born tired and
thers who are not. When you are trying to find out who
ou are, remember it is who you are in your environment
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The Future of Academic Cardiovascular Medicine October 4, 2005:1A–4And in your genetics. You have to consider all of this before
ou will be able to decide if you have the framework of an
nvestigator.
Once you know who you are, the next important question
s: what career do you want to follow? Do you want to be a
linician doing research, a pure researcher, an educator, or
o you want to be everything? A professional clinical
nvestigator is someone who spends 80% of his or her time
nvolved in clinical trials doing outcomes research or epide-
iology. This requires advanced training (i.e., MD, MPH,
nd so on). Conversely, the clinical investigator is in patient
are as a team player with a professional clinical investigator.
he clinical investigator does not need special training. The
hysician scientist spends 80% of his or her time doing
aboratory research while interfacing with the clinic. Ad-
anced research training is required (i.e., MD or MD/
hD), and this position is possibly the most threatened in
ajor medical centers. Finally, in defining the clinician/
cademician, there is the translational scientist. This indi-
idual conducts clinically oriented research (from molecules
o outcomes), pulling it all together as a team player.
dvanced research training, often a PhD degree, is re-
uired. The translational scientist is extremely important for
uite literally the translation of research; they are the bridge
etween the professional clinical investigator and the phy-
ician scientist. As you are planning your career, particularly
n the more basic research fields, you need a mentor and
nstitutional support that trains you to be a team member,
ecause there is nothing in modern research that does not
equire a number of people.
A few investigators will say they want to be an educator,
hich is fantastic, but you do not get a dime of research
oney for that; in that sense, being an educator is more of
vocation. However, can you be a triple threat: a researcher,
clinician, and an educator? It is possible if you are a
linician who has research talents as a clinical investigator
hat you will be able to do part-time or translational research
hile you are an educator on the side. You have to work very
ard for a career like this, but it is possible. Realize though
ou will not be seeing many patients, you still need to have
history of clinical excellence.
ONCLUSIONS
s teachers, we must teach medical students and residents
he incredible power of research, and we must feel it.
ellows and junior faculty members need a great training
nvironment, again a team effort, and it has to be from a
roup of good people. Importantly, we must also teach the
ublic and the politicians; we have to show we are creative,
hat we care, and that the work we do improves the state of
uman health as well as the economy.Finally, some of today’s fellows will become our leaders.
here is no question about that. In the past, a leader was a
ood manager, but the future will require strong commu-
ication skills, empathy, altruism, and the ability to create
hange. They will need people skills that allow them to align
nd motivate. Tomorrow’s leaders must be thick-skinned,
ecause they will be creating change against resistance. Also,
hey will possess the personal qualities of knowledge,
ctions, and values. You can say anything you want in a free
ociety, but if your neighbor does not believe what you say,
orget it. When you talk, you must have credibility and
eople will believe you; know what you are talking about,
nd people will listen. This is what is required of our next
eneration of leaders if they are going to make things
appen.
ddress correspondence to: Dr. Valentin Fuster, Mount Sinai
edical Center, One Gustave Levy Place, Box 1030, New York,
ew York 10029-6500. E-mail: valentin.fuster@mssm.edu.
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